Effect of multiple drug resistance on total medical costs among patients with intra-abdominal infections in China
- PMID: 29590138
- PMCID: PMC5873998
- DOI: 10.1371/journal.pone.0193977
Effect of multiple drug resistance on total medical costs among patients with intra-abdominal infections in China
Abstract
Background: Multiple drug resistant (MDR) intra-abdominal infections (IAIs) are associated with notable direct and societal costs. As previous studies have not considered the impact of MDR on the total medical costs (TMCs) of IAIs, the present one examines this, as well as further estimates the additional costs at a national level.
Methods: This is a retrospective study. Firstly, we randomly selected a sample of 40% of all inpatients discharged between 2014 and 2015 from a teaching hospital, due to limits in budget and the large number of patients. Then, we manually selected 254 patients with IAIs according to the International Classification of Disease, 10th revision, using electronic medical records. Eventually, 101 patients with IAIs (64 MDR patients and 37 non-MDR patients) were included after excluding cases without laboratory test results, any pathogens detected, or antimicrobial resistant pathogens. Univariate analysis and a generalized linear model were applied to assess the parameters associated with TMCs.
Results: Compared to non-MDR patients, those with MDR pathogens were significantly associated with higher TMCs, higher antimicrobial costs, higher antimicrobial usage, larger number of pathogens, and longer length of stay and were more likely to have insurance and combination antimicrobial therapy. In addition, the average TMC among patients with MDR pathogens was ¥ 131801, which is ¥ 90201 higher than those without MDR pathogens. If our results are applied to the whole country, the sum of all attributable TMCs was ¥ 37 billion. The societal costs, furthermore, were ¥111 billion in 2015.
Conclusion: Our results provide information that should lead to increased efforts to reduce inappropriate antimicrobial therapy, in order to decrease the emergence of MDR pathogens and to reduce their economic burden.
Conflict of interest statement
Similar articles
-
High excess costs of infections caused by carbapenem-resistant Gram-negative bacilli in an endemic region.Int J Antimicrob Agents. 2018 Apr;51(4):601-607. doi: 10.1016/j.ijantimicag.2017.12.012. Epub 2017 Dec 23. Int J Antimicrob Agents. 2018. PMID: 29277527
-
Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.Appl Health Econ Health Policy. 2015 Aug;13(4):369-79. doi: 10.1007/s40258-015-0162-9. Appl Health Econ Health Policy. 2015. PMID: 25761545
-
Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia.Infect Control Hosp Epidemiol. 2007 Jun;28(6):713-9. doi: 10.1086/517954. Epub 2007 May 14. Infect Control Hosp Epidemiol. 2007. PMID: 17520546
-
Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence.Expert Rev Anti Infect Ther. 2013 Mar;11(3):321-31. doi: 10.1586/eri.13.4. Expert Rev Anti Infect Ther. 2013. PMID: 23458771 Review.
-
Antimicrobial de-escalation strategies in hospitalized patients with pneumonia, intra-abdominal infections, and bacteremia.J Hosp Med. 2012;7 Suppl 1:S13-21. doi: 10.1002/jhm.983. J Hosp Med. 2012. PMID: 23737333 Review.
Cited by
-
Determining the impact of the COVID-19 pandemic on the consumption of antibiotics in Shaanxi province, China: an interrupted time-series analysis.Front Public Health. 2025 Feb 19;13:1475207. doi: 10.3389/fpubh.2025.1475207. eCollection 2025. Front Public Health. 2025. PMID: 40046123 Free PMC article.
-
Recent advances and perspectives of functionalized carbon dots in bacteria sensing.Mikrochim Acta. 2023 Aug 23;190(9):363. doi: 10.1007/s00604-023-05938-1. Mikrochim Acta. 2023. PMID: 37610450 Review.
-
Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies.BMC Med. 2020 Mar 6;18(1):38. doi: 10.1186/s12916-020-1507-2. BMC Med. 2020. PMID: 32138748 Free PMC article.
-
Risk Factors for Colonization With Multidrug-Resistant Bacteria in Urban and Rural Communities in Kenya: An Antimicrobial Resistance in Communities and Hospitals (ARCH) Study.Clin Infect Dis. 2023 Jul 5;77(Suppl 1):S104-S110. doi: 10.1093/cid/ciad223. Clin Infect Dis. 2023. PMID: 37406050 Free PMC article.
-
Epidemiological analysis of intra-abdominal infections in Italy from the Italian register of complicated intra-abdominal infections-the IRIS study: a prospective observational nationwide study.World J Emerg Surg. 2025 Mar 17;20(1):22. doi: 10.1186/s13017-025-00590-x. World J Emerg Surg. 2025. PMID: 40097999 Free PMC article.
References
-
- Lee Y R, McMahan D, McCall C, Perry G K. Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players. Drugs. 2015; 75:2097–2117. doi: 10.1007/s40265-015-0506-7 - DOI - PubMed
-
- Menichetti F, Sganga G. Definition and classification of intra-abdominal infections. Journal of Chemotherapy. 2013; 21:3–4. - PubMed
-
- Sartelli M, Catena F, Ansaloni L, Coccolini F, Corbella D, Moore E E, et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study. World Journal of Emergency Surgery. 2014; 9:37 doi: 10.1186/1749-7922-9-37 - DOI - PMC - PubMed
-
- Sartelli M, Catena F, di Saverio S, Ansaloni L, Coccolini F, Tranà C, et al. The Challenge of Antimicrobial Resistance in Managing Intra-Abdominal Infections. Surgical Infections. 2015; 16:213–220. doi: 10.1089/sur.2013.262 - DOI - PubMed
-
- World Health Organization. What is antimicrobial resistance? 2014. http://www.who.int/features/qa/75/en/. Accessed 7 October 2016.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials